Inozyme Pharma (INZY)
US Market

Inozyme Pharma (INZY) Financial Statements


Inozyme Pharma Financial Overview

Inozyme Pharma's market cap is currently ―. The company's EPS TTM is $-1.367; its P/E ratio is -3.90; Inozyme Pharma is scheduled to report earnings on August 7, 2024, and the estimated EPS forecast is $-0.40. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -22.02M$ -15.00M$ -16.64M$ -15.58M$ -17.40M
EBITDA$ -21.84M$ -14.79M$ -17.73M$ -16.32M$ -17.86M
Net Income Common Stockholders$ -23.35M$ -21.54M$ -16.64M$ -15.58M$ -17.40M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 166.15M$ 188.59M$ 192.44M$ 140.25M$ 130.93M
Total Assets$ 176.94M$ 200.85M$ 205.70M$ 150.93M$ 141.80M
Total Debt$ 46.63M$ 46.59M$ 34.10M$ 34.12M$ 26.66M
Net Debt$ -119.52M$ -142.00M$ -158.34M$ -106.13M$ -104.27M
Total Liabilities$ 58.11M$ 60.37M$ 45.49M$ 45.34M$ 38.45M
Stockholders Equity$ 118.81M$ 140.48M$ 160.21M$ 105.64M$ 103.35M
Cash Flow-
Free Cash Flow$ -24.57M$ -18.59M$ -18.88M$ -15.56M$ -17.95M
Operating Cash Flow$ -24.53M$ -18.49M$ -18.87M$ -15.55M$ -17.77M
Investing Cash Flow$ 10.39M$ -6.47M$ -44.62M$ -16.33M$ 13.77M
Financing Cash Flow$ 159.00K$ 12.52M$ 69.72M$ 23.64M$ 20.10M
Currency in USD

Inozyme Pharma Earnings and Revenue History

Inozyme Pharma Debt to Assets

Inozyme Pharma Cash Flow

Inozyme Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis